The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Next-generation CAR-T strategies aim to improve access and durability in myeloma
Binod Dhakal, MD, Medical College of Wisconsin, Milwaukee, WI, discusses the evolving landscape of next-generation CAR-T strategies in multiple myeloma, including allogeneic products, dual-targeted CAR-T therapies, and novel cell engineering approaches. Dr Dhakal highlights the need to improve access, durability of response, and safety for patients with relapsed/refractory disease, and explains how off-the-shelf and rapidly manufactured CAR-T products may help overcome current logistical and treatment limitations. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
In a relapsed fracture setting, we are very fortunate to have so many options with the CAR-T and bispecific and trispecific. But at the same time, there are some of the challenges which still exist, especially some of the patients relapsing despite these therapies, the safety of some of these therapies and access to a large number of patients. So I think there is an ongoing need to have some effective therapies, safer therapies, and at the same time, therapies that can be easily accessible or broadly accessible to a large number of patients...
In a relapsed fracture setting, we are very fortunate to have so many options with the CAR-T and bispecific and trispecific. But at the same time, there are some of the challenges which still exist, especially some of the patients relapsing despite these therapies, the safety of some of these therapies and access to a large number of patients. So I think there is an ongoing need to have some effective therapies, safer therapies, and at the same time, therapies that can be easily accessible or broadly accessible to a large number of patients. So I think at this time, you know, both dual-targeted CAR-T therapies with AZD0120 and the rapid manufacturing process and also dual-targeting could be an important option to overcome those limitations. Similarly, a product like CB-011, which is an allogeneic CAR-T, can also overcome some of the limitations using healthy donor T cells, giving rapid access to patients and also manufacturing on a larger scale. So I think given the fact that myeloma remains an incurable disease, it is important to have these next-generation therapies so that a large number of patients do benefit from these therapies.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
